Drugs That Distort Urinary Sex Steroid Metabolite Testing

What Urinary Sex Steroid Metabolites Actually Measure

A urinary sex steroid metabolite panel quantifies how the body produces, converts, and eliminates estrogens, androgens, and progesterone. Unlike a single serum estradiol draw, this test captures downstream metabolites: 2-OHE1, 4-OHE1, 16α-OHE1, estriol, and their methylated forms, alongside testosterone metabolites like androsterone, etiocholanolone, and 5α-DHT derivatives 1.

The 2-OHE1 to 16α-OHE1 ratio has received particular attention in breast cancer risk research. A prospective study within the EPIC cohort (N=663 cases, 1,765 controls) found that a higher urinary 2-OHE1:16α-OHE1 ratio was associated with a modest reduction in postmenopausal breast cancer risk 2. The ratio reflects Phase I hepatic hydroxylation activity, primarily governed by CYP1A1 and CYP3A4. Any drug that induces or inhibits these enzymes will shift the ratio independent of actual hormonal status 3.

Dried urine panels such as the DUTCH Complete have expanded clinical use beyond 24-hour collections. They add cortisol metabolites and organic acids like methylmalonate and 8-OHdG. The trade-off is identical to traditional collection: every exogenous compound metabolized through the same hepatic and renal pathways can contaminate the readout.

Combined Oral Contraceptives: The Biggest Confounder

Combined oral contraceptives (COCs) suppress the hypothalamic-pituitary-ovarian (HPO) axis through ethinylestradiol and a progestin. That suppression reduces endogenous estradiol production by approximately 50 to 90%, depending on the formulation and individual pharmacokinetics 4. Metabolite panels then reflect the synthetic estrogen and progestin rather than native hormones.

Ethinylestradiol is metabolized through the same CYP1A1 hydroxylation pathway as endogenous estradiol. It generates its own 2-OH and 16α-OH products. A clinician reviewing the panel cannot separate drug-derived metabolites from endogenous ones. The result is a hybrid readout with no clinical meaning for risk stratification.

The Endocrine Society's 2014 clinical practice guideline on testosterone therapy in women notes that oral estrogens also raise sex hormone-binding globulin (SHBG), which lowers free testosterone and, downstream, its urinary metabolites 5. This creates a double distortion: estrogen metabolites are contaminated by the synthetic compound, and androgen metabolites are suppressed by SHBG-driven sequestration.

Washout recommendation: Most functional and integrative endocrinology references suggest stopping COCs at least 6 to 8 weeks before collection. The 2019 AACE/ACE menopause guideline supports the general principle that exogenous hormones should be discontinued for an adequate washout period before diagnostic hormone testing 6.

Exogenous Hormone Replacement Therapy

Transdermal, oral, sublingual, and injectable estradiol all deliver parent estradiol that is then metabolized through Phase I and Phase II hepatic pathways. Urinary panels will capture these metabolites faithfully, but the clinical question shifts: are you testing how the patient metabolizes their prescription, or are you trying to assess endogenous production?

If the goal is to evaluate HRT metabolism (for instance, confirming adequate 2-hydroxylation and COMT-mediated methylation of estrogen), the patient should continue therapy through collection. If the goal is baseline endogenous status, exogenous estradiol must be cleared. Estradiol valerate has a terminal half-life of roughly 12 to 36 hours depending on route, but metabolite pools may take 2 to 4 weeks to fully normalize after discontinuation 7.

Testosterone replacement (injections, gels, pellets) floods androgen metabolite pathways. A man on 200 mg testosterone cypionate weekly will show elevated androsterone, etiocholanolone, and 5α-androstanediol levels that reflect injected drug, not adrenal or gonadal production. The Endocrine Society's 2018 guideline on testosterone therapy in men with hypogonadism recommends measuring serum testosterone at trough for monitoring, not urinary metabolites, precisely because exogenous dosing confounds urinary panels 8.

Progesterone supplementation (oral micronized progesterone, vaginal inserts) similarly elevates pregnanediol, the primary urinary progesterone metabolite. Oral micronized progesterone also produces significant levels of allopregnanolone and other 5α-reduced neurosteroids that appear in urine 9.

Aromatase Inhibitors and SERMs

Aromatase inhibitors (anastrozole, letrozole, exemestane) block CYP19A1-mediated conversion of androgens to estrogens. In postmenopausal women, letrozole 2.5 mg daily suppresses plasma estradiol to below 2.7 pg/mL in most patients, as demonstrated in the BIG 1-98 trial (N=8,010) 10. Urinary estrogen metabolites drop proportionally, often to near-undetectable levels on standard assays.

This suppression is expected and clinical. But if the test was ordered to evaluate estrogen detox pathway ratios, the denominator collapses. A 2-OHE1:16α-OHE1 ratio calculated from values at or below the lower limit of quantification is statistically meaningless.

Selective estrogen receptor modulators (SERMs) like tamoxifen do not suppress estrogen production. They may even raise serum estradiol in premenopausal women through HPO axis feedback. Tamoxifen's effect on urinary metabolites is subtler: it competes for CYP enzyme binding, potentially shifting the hydroxylation ratio without changing total output. A small crossover study (N=30) showed tamoxifen increased the 2-OHE1:16α-OHE1 ratio modestly over 3 months of use 11.

5-Alpha Reductase Inhibitors and GnRH Agonists

Finasteride and dutasteride block the 5α-reductase enzyme that converts testosterone to dihydrotestosterone (DHT). This reroutes androgen metabolism. Urinary 5α-reduced metabolites (androsterone, 5α-androstanediol glucuronide) drop, while 5β-reduced metabolites (etiocholanolone) remain stable or rise 12. A clinician unaware of the drug will see an abnormal 5α:5β ratio and may misinterpret it as a 5α-reductase deficiency or altered hepatic function.

Dutasteride inhibits both Type I and Type II 5α-reductase, producing a more complete suppression of 5α-metabolites than finasteride alone. The suppression persists for weeks after discontinuation given dutasteride's long half-life (approximately 5 weeks) 13.

GnRH agonists (leuprolide, goserelin) and antagonists (degarelix, relugolix) suppress gonadotropins after an initial flare (agonists only). In men, they reduce testosterone to castrate levels (<50 ng/dL). In women, they produce a medical menopause. All downstream urinary metabolites, estrogen, androgen, and progesterone, will reflect this pharmacologic suppression rather than native glandular function 14.

Supplements and OTC Compounds That Interfere

High-dose biotin is the most documented supplement interferent for immunoassay-based hormone panels. The FDA issued a 2017 safety communication warning that biotin above 5 mg/day can cause falsely high or falsely low results in immunoassays that use streptavidin-biotin technology 15. While LC-MS/MS-based urinary panels are not affected by biotin interference, many point-of-care and reference-lab immunoassays still use this chemistry.

DIM (3,3'-diindolylmethane) and I3C (indole-3-carbinol) are widely marketed as estrogen metabolism support. Both are potent CYP1A1 inducers. A randomized trial (N=60) showed that I3C at 400 mg/day significantly increased the urinary 2-OHE1:16α-OHE1 ratio over 12 weeks 16. This is the intended effect of the supplement, but if a panel is ordered to assess native estrogen metabolism, DIM/I3C use renders the ratio uninterpretable as a baseline.

Other notable interferents:

• Cruciferous vegetable concentrates (sulforaphane, broccoli seed extract): CYP1A1/1A2 induction, similar mechanism to DIM 17
• Calcium D-glucarate: promoted as a beta-glucuronidase inhibitor, it may reduce enterohepatic recirculation of estrogens and lower total urinary estrogen output
• High-dose vitamin C (>2 g/day): can alter urinary pH sufficiently to affect conjugate stability in 24-hour collections
• St. John's Wort: a strong CYP3A4 inducer that accelerates estrogen clearance and shifts hydroxylation patterns 18

Prescription Drugs With Indirect Effects

Several drug classes distort the panel through enzyme induction, inhibition, or altered renal handling rather than direct hormonal activity.

Rifampin is the textbook CYP3A4 inducer. It accelerates estradiol clearance by 2- to 3-fold, which is why the CDC warns that rifampin reduces oral contraceptive efficacy 19. The same induction lowers total urinary estrogen metabolites.

Phenytoin, carbamazepine, and phenobarbital are broad-spectrum CYP inducers. They lower circulating estradiol and alter the hydroxylation ratio. The American Academy of Neurology notes that enzyme-inducing antiepileptic drugs reduce contraceptive hormone levels by 40 to 50% 20.

Ketoconazole inhibits CYP3A4 and CYP17A1. It suppresses adrenal and gonadal steroid synthesis directly. Urinary androgen metabolites drop within days of initiation.

Spironolactone is an androgen receptor antagonist that also inhibits 17α-hydroxylase. It reduces androgen production and blocks receptor-mediated feedback, which can alter both serum and urinary androgen profiles. It is commonly prescribed in PCOS and transgender care, and should be noted on any requisition for urinary steroid metabolites 21.

Metformin does not directly alter steroidogenesis, but in PCOS it improves insulin sensitivity, which lowers ovarian androgen production over weeks to months. A Cochrane review (N=8,721 across 44 trials) confirmed that metformin reduces serum testosterone in women with PCOS 22. The downstream effect on urinary androgen metabolites is modest but measurable.

How to Prepare Patients for Accurate Collection

The most reliable results come from patients who have disclosed every medication and supplement to the ordering clinician. A practical pre-test protocol includes these steps.

Stop (with physician approval) at least 6 to 8 weeks before testing: combined oral contraceptives, hormonal IUDs with systemic absorption (debated), estrogen patches/gels, testosterone injections/gels/pellets, and oral progesterone.

Stop 2 to 4 weeks before testing: DIM, I3C, cruciferous extracts, calcium D-glucarate, high-dose biotin (>5 mg), and St. John's Wort.

Document but do not necessarily stop: aromatase inhibitors (if testing is to monitor drug effect), finasteride/dutasteride (if the clinical question requires it), GnRH agonists/antagonists, antiepileptic drugs, and spironolactone. These drugs should be clearly listed on the lab requisition so the interpreting provider can adjust reference ranges.

Collect at the right time. For cycling individuals, luteal-phase collection (days 19 to 22 of a regular cycle) captures progesterone metabolites at their peak. For postmenopausal individuals or those on GnRH suppression, timing is less critical, but morning first-void samples (for dried urine) should be consistent across panels 23.

Avoid intense exercise in the 24 hours before collection. Acute high-intensity exercise transiently raises cortisol and DHEA metabolites, which can confound adrenal sections of combined panels 24.

Understanding Normal Ranges and What Shifts Them

Reference ranges for urinary sex steroid metabolites vary by laboratory, assay method (GC-MS, LC-MS/MS, immunoassay), and patient demographics. The 2-OHE1:16α-OHE1 ratio in untreated premenopausal women generally falls between 1.0 and 3.0 in luteal-phase samples, though optimal targets remain debated 2.

Total urinary estrogen metabolites decline steeply across the menopause transition. A cross-sectional analysis from the Nurses' Health Study found that total urinary estrogens in postmenopausal women were approximately 40% of premenopausal luteal-phase levels 25.

Androgen metabolites differ by sex and age. Men excrete roughly 3 to 5 mg of total 17-ketosteroids per 24 hours, while women excrete 1 to 3 mg, with progressive decline after age 40 in both sexes. Adrenal contributions (DHEA-S-derived metabolites) remain substantial even after gonadal decline, making it difficult to separate gonadal from adrenal sources without paired serum testing 26.

Any value outside the expected range should prompt a medication and supplement review before repeating the test or initiating therapy. A single elevated 4-OHE1 value in a patient taking DIM, for example, may simply reflect the known CYP1A1 induction redirecting metabolism away from the 4-OH pathway, not a genuine shift in genotoxic estrogen exposure.